Upcoming Webinars

Data Privacy and Digital Health: The Manufacturers/Payers Perspective
Wednesday, July 27, 2022
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Differentiating between Patient Preferences, Patient Reported Outcomes and Patient Engagement
Wednesday, September 7, 2022
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Fit for Local Context? Establishing or Improving Deliberative Processes for HTA
Friday, September 30, 2022
09:00AM EDT | 1:00PM UTC | 3:00PM CEST

Most Recent


Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Sustainable Access to Biosimilars in the USA and Latin America: Challenges and Potential Solutions

Jun 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Accelerating Patient Access to Next Generation Sequencing

May 2022

Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.

Clinical Outcomes



Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Leveraging the Value of Clinical Outcome Assessment (COA) Data Beyond Labelling

Apr 2022

Speakers will discuss the many uses of COA data gathered during patient-focused drug development, including benefit/risk evaluation, HTA, access decisions, policy decisions, and clinician and patient decision-making.

Data Privacy as a Hurdle or Enabler for Digital Health Implementation? The Legal Framework

Apr 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.


Economic Evaluation



Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Accelerating Patient Access to Next Generation Sequencing

May 2022

Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.

Value-Based Payment in Asia Pacific: Case Studies and Lessons Learned

Apr 2022

Health systems in Asia Pacific regions are under tremendous pressure to deal with the rising costs, unequal access to service, and uneven quality of care. More and more healthcare systems across the region have increasingly embraced a value-based health care (VBHC) agenda. How can we maximize value for money and optimize patient outcomes? How should healthcare be delivered and reimbursed? In light of these issues, this webinar brings together a panel of experts to discuss the current situation of value-based payment in the Asia Pacific region and beyond, challenges and opportunities for VBHC implementation in the region.


Health Technology Assessment



Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Accelerating Patient Access to Next Generation Sequencing

May 2022

Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.

Value-Based Payment in Asia Pacific: Case Studies and Lessons Learned

Apr 2022

Health systems in Asia Pacific regions are under tremendous pressure to deal with the rising costs, unequal access to service, and uneven quality of care. More and more healthcare systems across the region have increasingly embraced a value-based health care (VBHC) agenda. How can we maximize value for money and optimize patient outcomes? How should healthcare be delivered and reimbursed? In light of these issues, this webinar brings together a panel of experts to discuss the current situation of value-based payment in the Asia Pacific region and beyond, challenges and opportunities for VBHC implementation in the region.


Real-World Data & Information Systems


The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Delivering Evidence-Based Access in Rare Diseases: The Challenges in SMA

Apr 2022

This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.

Data Privacy as a Hurdle or Enabler for Digital Health Implementation? The Legal Framework

Apr 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

Bariatric Surgery Reimbursement Seminar

Mar 2022

Experts from around the world will be sharing their experience about obesity treatment and reimbursement policies in their different countries. The event will consist of 7 expert presentations followed by a round table discussion with an opportunity for the audience to ask questions.


Patient-Centered Research



Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Data Privacy as a Hurdle or Enabler for Digital Health Implementation? The Legal Framework

Apr 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

Improving Performance: Selection and Development of PerfO Assessments to Capture Clinical Benefit: Performance Outcome Assessment Emerging Good Practices Task Force

Jan 2022

This webinar will be useful for researchers, regulators, academics, industry sponsors, and instrument developers in the clinical outcomes assessment (COA) field working on the development, evaluation, and implementation of performance outcome (PerfO) measures for use in capturing clinical benefits in treatment trials for medical label claims.

Methodical & Statistical Research



Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Delivering Evidence-Based Access in Rare Diseases: The Challenges in SMA

Apr 2022

This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.

Supporting Covid19-Related Decision Making with Health Preference Research

Feb 2021

Many preference researchers have been quick to respond to this need and have conducted empirical COVID19 studies to better understand the value of health and health-related policies.

Health Policy & Regulatory



Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Sustainable Access to Biosimilars in the USA and Latin America: Challenges and Potential Solutions

Jun 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society.

Accelerating Patient Access to Next Generation Sequencing

May 2022

Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.

Study Approaches


Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy

Oct 2020

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.

Why and How to Use Qualitative Research Methods in Conjunction with Discrete Choice Experiments in Health Care

Jun 2020

This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.

Adding Depth to Observational Research through Data Linkage

Apr 2020

This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.


Epidemiology & Public Health


The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

ISPOR/IVI COVID Webinar #5: Using VA/HTA in Pursuing Innovation and Access in a Pandemic

Nov 2020

This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.

ISPOR/IVI COVID Webinar #4: The Role of Public Health – How can VA/HTA Inform Pandemic Policy Interventions and Public Resource Allocation?

Nov 2020

COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?

ONE HEALTH Perspectives on HEOR

Oct 2020

This webinar features a range of international speakers who will introduce several One Health-related topics as they pertain to HEOR, with a view gauging interest in the formation of an ISPOR Animal and One Health Special Interest Group (SIG).


Specialized Treatment Areas


Health Preference Research in the Context of Gene Therapy in Rare Diseases

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Biosimilars: Market Access Challenges & Opportunities Worldwide

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.


Specific Diseases & Conditions


Challenges in Assessing the Clinical and Economic Value of Future Treatments for Alzheimer’s Disease

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Value Assessment in Alzheimer's Disease: A Focus on Equity

Nov 2020

This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

Valuing Future Alzheimer’s Disease Medicines: Extending the Paradigm

Oct 2020

This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.

Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×